Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Alvopetro Announces Q3 2026 Financial Results and an Operational Update Including 183-G2 Well Results
